Help complete your enrollment online
If you have been directed to this site by your doctor, it may mean your signature is needed to complete your Interconnect enrollment. Click the button below to electronically sign your Patient Authorization form.
If you have been directed to this site by your doctor, it may mean your signature is needed to complete your Interconnect enrollment. Click the button below to electronically sign your Patient Authorization form.
You are now leaving Interconnect
Any information you provide after you leave this site and enter another site will be subject to the other website’s privacy policy and terms and conditions. Interconnect is not responsible for the use, security, or disclosure of any information you may provide to another site.
The information on this site is intended for healthcare professionals in the United States, its territories, and Puerto Rico, and is not intended for the general public.
Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., announced its decision to voluntarily withdraw OCALIVA® (obeticholic acid) from the US market for the treatment of primary biliary cholangitis (PBC), a rare, progressive liver disease.
Healthcare professionals can contact Medical Information at medinfo@interceptpharma.com or call 1-844-782-4278. Patients should talk to their healthcare professionals and may also contact Intercept's Patient Support Services (Interconnect) at 1-844-622-4278.
For all other inquiries please visit: https://www.interceptpharma.com/
Please click here for Full Prescribing Information and Medication Guide for OCALIVA.